[News] 2017 ASH Meeting

Youn H Kim (Stanford University, Stanford, CA, USA) presented results from MAVORIC, an open-label, international, randomised, phase 3 trial comparing mogamulizumab (an anti-chemokine receptor 4 antibody) with vorinostat in 372 patients with previously treated cutaneous T-cell lymphoma. Investigator-assessed progression-free survival (primary endpoint) was significantly longer with mogamulizumab than with vorinostat (median 7 ·7 months [95% CI 5·7–10·3] vs 3·1 months [2·9–4·1]; hazard ratio [HR] 0·53 [95% CI 0·41–0·69]; p
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research